With an intricate symptom pattern involving a dysregulated host response to
infection, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can cause severe
inflammation and
cytokine storms,
acute respiratory distress syndrome, coagulopathy, multi-organ failure, and finally death. The uniqueness of this case report lies in the nature of the therapeutic intervention performed. While numerous studies are available on both the use of therapeutic
plasma exchange in
coronavirus disease 2019 (COVID-19) patients and convalescent plasma transfusion as separate treatment methods, there is very little information regarding the combination of these procedures. We present the case of a 52-year-old male, unvaccinated for
COVID-19, who tested positive on
reverse transcriptase polymerase chain reaction for SARS-CoV-2 for the first time and presented in the emergency room with
fever,
chills, severe
cough,
tachypnea,
tachycardia, and
dyspnea that started two days before presentation. Upon rapid assessment, the patient showed signs of acute
respiratory failure, so it was decided to transfer the patient to the intensive care unit,
COVID-19 ward, after preliminary radiological examination. For the next 24 days, the patient was stationed in the intensive care unit, where he was closely monitored and treated. Invasive
mechanical ventilation was required following the initial worsening of his respiratory status. We performed therapeutic
plasma exchange on the first day of his stay in the intensive care unit, and immediately after the procedure, the patient was transfused with 500 mL of convalescent plasma from healthy donors. The patient's condition improved over the next few days, which led to the cessation of
mechanical ventilation and, after treating the
superinfection, the patient was discharged home, making a full recovery. The early initiation of therapeutic
plasma exchange followed by transfusion of convalescent plasma in severe and critical forms of
COVID-19 may reduce the risk of the progression of the disease and ultimately reduce the risk of negative outcomes in a selected group of patients.